BridgeBio Pharma has been granted a patent for high-load tablet formulations of AG10 or its salt, containing at least 40% AG10 by weight and various pharmaceutical excipients. The tablet formulation includes specific percentages of fillers, disintegrants, and lubricants, with high-grade microcrystalline cellulose as a filler. GlobalData’s report on BridgeBio Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BridgeBio Pharma, was a key innovation area identified from patents. BridgeBio Pharma's grant share as of May 2024 was 10%. Grant share is based on the ratio of number of grants to total number of patents.
High-load tablet formulation of ag10 with specific excipients
A recently granted patent (Publication Number: US12005043B2) discloses a tablet formulation for the treatment of transthyretin amyloid (ATTR) cardiomyopathy and polyneuropathy. The formulation comprises AG10 or a pharmaceutically acceptable salt thereof, along with fillers, disintegrants, and lubricants. The tablet formulation includes specific weight percentages of AG10 (ranging from 40% to 85%), fillers (5% to 55%), disintegrants (3% to 8%), and lubricants (0.5% to 3%). The fillers used in the formulation are high-grade microcrystalline cellulose with specific characteristics, ensuring the tablet's efficacy in treating the mentioned conditions.
Moreover, the patent claims detail various specific compositions within the tablet formulation, such as the percentage of AG10, fillers, disintegrants, and lubricants. The tablet formulation is designed to achieve a high dissolution rate, with the tablet being at least 75% dissolved after a specified dissolution test. Additionally, the patent includes methods for treating ATTR cardiomyopathy and polyneuropathy by administering the tablet formulation. The patent emphasizes the importance of the specific composition and characteristics of the tablet formulation in effectively treating these medical conditions, highlighting the innovative approach taken in formulating the treatment.
To know more about GlobalData’s detailed insights on BridgeBio Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
